Advertisement
Advertisement
LENZ
LENZ Therapeutics, Inc. Common Stock
14.23
USDSponsored
+0.26
+1.86%
Feb 06, 15:59 UTC -5
Closed
After-Market
14.24
+0.01
+0.07%
LENZ Earnings Reports
Positive Surprise Ratio
LENZ beat 9 of 18 last estimates.
50%
Next Report
Date of Next Report
Mar 09, 2026
Estimate for Q4 25 (Revenue/ EPS)
$1.93M
/-$0.99
Implied change from Q3 25 (Revenue/ EPS)
-84.58%
/+67.80%
Implied change from Q4 24 (Revenue/ EPS)
--
/+115.22%
LENZ Therapeutics, Inc. Common Stock earnings per share and revenue
On Nov 05, 2025, LENZ reported earnings of -0.59 USD per share (EPS) for Q3 25, beating the estimate of -0.72 USD, resulting in a 18.10% surprise. Revenue reached 12.50 million, compared to an expected 6.96 million, with a 79.48% difference. The market reacted with a -23.46% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 8 analysts forecast an EPS of -0.99 USD, with revenue projected to reach 1.93 million USD, implying an increase of 67.80% EPS, and decrease of -84.58% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
Immunovant, Inc. Common Stock
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+16.27%
Adaptive Biotechnologies Corporation Common Stock
Report Date
Feb 05, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.09
Surprise
+51.33%
FAQ
What were LENZ Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, LENZ Therapeutics, Inc. Common Stock reported EPS of -$0.59, beating estimates by 18.1%, and revenue of $12.50M, 79.48% above expectations.
How did the market react to LENZ Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -23.46%, changed from $28.05 before the earnings release to $21.47 the day after.
When is LENZ Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 09, 2026.
What are the forecasts for LENZ Therapeutics, Inc. Common Stock's next earnings report?
Based on 8
analysts, LENZ Therapeutics, Inc. Common Stock is expected to report EPS of -$0.99 and revenue of $1.93M for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement